Collagen for tendon (not cartilage)

This entry exists to separate two claims the marketing merges. Tendon and cartilage are different tissues with different collagen, different vasculature and different turnover, and most of the evidence people cite for "collagen builds connective tissue" was collected in tendon and ligament.

That evidence is worth understanding on its own terms — partly because it is better designed than the cartilage literature, and partly because that is exactly why it has produced clearer negative results.

The founding result

Eight healthy men, a randomized double-blind crossover, and 5 or 15 g of vitamin C–enriched gelatin taken an hour before six minutes of rope skipping, three times a day for three days.

The 15 g dose doubled serum PINP, a marker of type I collagen synthesis. Serum taken from the supplemented subjects, applied to engineered ligaments in a dish, increased their collagen content and improved their mechanics.

It is an elegant study and it generated the whole pre-training timing protocol. It also has an n of eight, uses a systemic circulating marker that reports whole-body collagen synthesis rather than anything tissue-specific, and its tissue arm was in vitro.

The lab's own replication came up short

Two years later the same group ran it again in ten recreationally active men, comparing placebo against 15 g of vitamin C–enriched gelatin, hydrolysed collagen, or a gummy containing both.

Their finding, in their own words: PINP "tended to increase ∼20% from baseline in the gelatin and HC interventions but not the placebo or gummy. However, large variability was observed, which precluded significance for any treatment."

The gummy formulation — the convenient consumer format — was inert.

That is not a refutation, and the direction was preserved. But when the originating lab cannot reach significance on its own endpoint at the same dose, the effect is smaller or noisier than the first paper suggested.

Then the endpoint moved to actual tissue

Two independent trials asked whether any of this shows up where it would have to.

Fifteen weeks, MRI, resistance training. Thirty-nine young men took 15 g of specific bioactive collagen peptides or placebo daily through a standardized three-times-weekly lower-body programme, with patellar tendon cross-sectional area, aponeurosis area and mechanical properties measured before and after.

Nothing. Verbatim: "No between-group differences were detected for any of the tendinous tissue adaptations." The p-values ranged from 0.365 to 0.877. Both groups adapted — and placebo was numerically higher on every mechanical measure, with tendon stiffness up 20.9 percent against 17.3 percent on collagen.

Isotope tracing with biopsies. Forty-five recreational athletes received infused labelled phenylalanine, did resistance exercise, then took 30 g whey, 30 g collagen, or nothing, with muscle biopsies over five hours. This is the gold-standard method — it measures the fractional synthesis rate of connective protein directly rather than inferring it from a blood marker.

Muscle connective protein synthesis: 0.072 %/h on whey, 0.068 on collagen, 0.058 on placebo, p = 0.09. No significant difference between groups. Whey did raise myofibrillar synthesis; collagen raised nothing above placebo.

What survives

The positive tendon trials are real but come with a pattern. A 14-week trial found Achilles tendon cross-sectional area up 11.0 percent on 5 g collagen peptides against 4.7 percent on placebo — but tendon stiffness and muscle strength were null between groups, and the study comes from the manufacturer-affiliated group in Freiburg with a Collagen Research Institute co-author.

The most clinically interesting result is in injured tendon rather than healthy tendon: a crossover pilot in twenty people with chronic mid-portion Achilles tendinopathy found collagen peptides plus calf strengthening improved VISA-A by 12.6 points against 5.3 for exercise alone. Twenty people, and a pilot — but it is the one design where a substrate effect might plausibly matter, because the tissue is actually trying to repair.

What this means for the cartilage question

Two things, and they cut opposite ways.

The tendon literature is the most rigorous test the collagen hypothesis has faced, because tendon is biopsiable and imageable in ways articular cartilage is not. It largely failed that test at the tissue level. That should lower confidence in cartilage claims resting on the same mechanism.

But tendon is not cartilage. It is type I collagen, better vascularised, and adapts to mechanical load through different signalling. Pro-Hyp's measured effects — aggrecan expression, glycosaminoglycan deposition — are chondrocyte behaviours with no tendon equivalent. A null result in tendon does not mechanically transfer to cartilage any more than a positive one would.

The honest position is that the strongest available evidence for a tissue-level collagen effect in humans is negative, and it was collected in a different tissue from the one this site is about.